A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors

Lian Liu, Wen Zhang, Wenhua Li, Fangfang Lv, Zuguang Xia, Sheng Zhang, Wen Liu, Anthe S Zandvliet, Sylvia Waajen, Li Xin Zhang, Li Yan, Jin Li, Lian Liu, Wen Zhang, Wenhua Li, Fangfang Lv, Zuguang Xia, Sheng Zhang, Wen Liu, Anthe S Zandvliet, Sylvia Waajen, Li Xin Zhang, Li Yan, Jin Li

Abstract

Purpose: Ridaforolimus (AP23573, MK-8669 or deforolimus) is an inhibitor of mammalian target of rapamycin (mTOR), an important regulator in the cell survival pathway. This open-label, single center phase I study aimed to investigate the pharmacokinetic (PK) and safety profiles of ridaforolimus in Chinese patients with treatment-refractory advanced or relapsed solid tumors. The PK data generated from these Chinese patients were further compared with those previously reported in Caucasian and Japanese patient populations.

Experimental design: The patients were given an oral dose of 40 mg of ridaforolimus on Day 1 of the study. On Day 8, patients were initiated on a treatment regimen that comprised a once daily dose of 40 mg of ridaforolimus for five consecutive days, followed by a 2-day off-drug interval. Patients repeated this regimen until disease progression or intolerance. Blood samples were collected at specific times pre- and post-treatment to establish the PK profile of ridaforolimus in all patients.

Results: Fifteen patients were given at least one dose of 40 mg of ridaforolimus. The median absorption lag-time was 2 hours, the median Tmax was 4 hours and the mean elimination half-life was 53 hours. The accumulation ratio for AUC(0-24hr) was 1.3 on day 19 (steady state)/day 1 (after a single dose). The most common drug-related adverse events (AEs) that occurred in ≥40% of patients were stomatitis, proteinuria, leukopenia, hyperglycemia, and pyrexia. Grade 3/4 drug-related AEs were anemia, stomatitis, fatigue, thrombocytopenia, constipation, gamma glutamyltransferase increase, and proteinuria. All 11 evaluable patients achieved stable disease.

Conclusions: Oral ridaforolimus at a daily dose of 40 mg were generally well tolerated in Chinese patients with advanced or refractory solid tumors. Adverse events and PK profiles of ridaforolimus in this study were similar to those from Caucasian and Japanese patients reported previously.

Figures

Figure 1
Figure 1
Blood concentration profiles (arithmetic mean +/− SD) of ridaforolimus following administration of a single oral dose or multiple once daily dosages of 40 mg of ridaforolimus in Chinese patients with advances or metastatic solid tumors (Day 1 n = 15 and Day 19 n = 13).

References

    1. Yuan RR, Kay A, Berg WJ, Lebwohl D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol. 2009;2:45. doi: 10.1186/1756-8722-2-45.
    1. Shor B, Gibbons JJ, Abraham RT, Yu K. Targeting mtor globally in cancer: thinking beyond rapamycin. Cell Cycle. 2009;8(23):3831–3837. doi: 10.4161/cc.8.23.10070.
    1. Ciuffreda L, Di Sanza C, Incani UC, Milella M. The mtor pathway: a new target in cancer therapy. Curr Cancer Drug Targets. 2010;10(5):484–495. doi: 10.2174/156800910791517172.
    1. Memmott RM, Dennis PA. Akt-dependent and -independent mechanisms of mtor regulation in cancer. Cell Signal. 2009;21(5):656–664. doi: 10.1016/j.cellsig.2009.01.004.
    1. Wang L, Shi WY, Wu ZY. et al.Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma. J Hematol Oncol. 2010;3:30. doi: 10.1186/1756-8722-3-30.
    1. Rivera VM, Squillace RM, Miller D, Berk L, Wardwell SD, Ning Y. et al.Ridaforolimus (AP23573; MK-8669), a potent mtor inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther. 2011;10(6):1059–1071. doi: 10.1158/1535-7163.MCT-10-0792.
    1. Amato RJ, Wilding G, Bubley G, Loewy J, Haluska F, Gross ME. Safety and preliminary efficacy analysis of the mtor inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer. Clin Genitourin Cancer. 2012;10(4):232–238. doi: 10.1016/j.clgc.2012.05.001.
    1. Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D'Amato GZ. et al.Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol. 2012;30(1):78–84. doi: 10.1200/JCO.2011.35.6329.
    1. Rizzieri DA, Feldman E, Dipersio JF, Gabrail N, Stock W, Strair R. et al.A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2008;14(9):2756–2762. doi: 10.1158/1078-0432.CCR-07-1372.
    1. Blay JY, Chawla SP, Ray-Coquard I, Cesne AL, Staddon AP, Milhem MM. et al.Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (≥ 24 months) overall survival results. J Clin Oncol. 2012;30(Suppl) abstr 10010: .
    1. Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M. et al.Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol. 2008;26(3):361–367. doi: 10.1200/JCO.2007.12.0345.
    1. Hartford CM, Desai AA, Janisch L, Karrison T, Rivera VM, Berk L. et al.A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res. 2009;15(4):1428–1434. doi: 10.1158/1078-0432.CCR-08-2076.
    1. Seki Y, Yamamoto N, Tamura Y, Goto Y, Shibata T, Tanioka M. et al.Phase I study for ridaforolimus, an oral mtor inhibitor, in japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012;69(4):1099–1105. doi: 10.1007/s00280-011-1788-4.
    1. Mita MM, Britten CD, Poplin E, Tap WD, Carmona A, Yonemoto L. et al.Deforolimus trial 106: a phase I trial evaluating 7 regimens of oral deforolimus (AP23573; MK-8669) J Clin Oncol. 2008;26(Suppl) abstr 3509.
    1. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S. et al.Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–456. doi: 10.1016/S0140-6736(08)61039-9.
    1. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR. et al.Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22(5):909–918. doi: 10.1200/JCO.2004.08.185.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する